NASDAQ:EYES - Second Sight Medical Products Stock Price, News & Analysis

$0.81
+0.03 (+3.85 %)
(As of 08/18/2019 11:00 AM ET)
Today's Range
$0.71
Now: $0.81
$0.82
50-Day Range
$0.7601
MA: $0.82
$0.90
52-Week Range
$0.63
Now: $0.81
$1.98
Volume406,600 shs
Average Volume132,608 shs
Market Capitalization$100.60 million
P/E RatioN/A
Dividend YieldN/A
Beta2.27
Second Sight Medical Products, Inc develops, manufactures, and markets implantable visual prosthetics that are intended to deliver artificial vision to blind individuals. It develops technologies to treat the population of sight-impaired individuals. The company offers the Orion Visual Cortical Prosthesis System, an implanted cortical stimulation device, which is intended to provide useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury. Read More…

Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EYES
CUSIPN/A
Phone818-833-5000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$6.90 million
Book Value$0.17 per share

Profitability

Net Income$-35,090,000.00
Net Margins-553.01%

Miscellaneous

Employees123
Market Cap$100.60 million
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable

Receive EYES News and Ratings via Email

Sign-up to receive the latest news and ratings for EYES and its competitors with MarketBeat's FREE daily newsletter.


Second Sight Medical Products (NASDAQ:EYES) Frequently Asked Questions

What is Second Sight Medical Products' stock symbol?

Second Sight Medical Products trades on the NASDAQ under the ticker symbol "EYES."

How were Second Sight Medical Products' earnings last quarter?

Second Sight Medical Products Inc (NASDAQ:EYES) announced its quarterly earnings results on Tuesday, August, 6th. The medical device company reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.06) by $0.01. The medical device company earned $1.28 million during the quarter, compared to analyst estimates of $0.45 million. Second Sight Medical Products had a negative net margin of 553.01% and a negative return on equity of 248.94%. View Second Sight Medical Products' Earnings History.

When is Second Sight Medical Products' next earnings date?

Second Sight Medical Products is scheduled to release their next quarterly earnings announcement on Wednesday, November 6th 2019. View Earnings Estimates for Second Sight Medical Products.

What price target have analysts set for EYES?

1 brokers have issued 12 month target prices for Second Sight Medical Products' stock. Their predictions range from $5.00 to $5.00. On average, they anticipate Second Sight Medical Products' share price to reach $5.00 in the next twelve months. This suggests a possible upside of 517.3% from the stock's current price. View Analyst Price Targets for Second Sight Medical Products.

What is the consensus analysts' recommendation for Second Sight Medical Products?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Second Sight Medical Products in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Second Sight Medical Products.

Has Second Sight Medical Products been receiving favorable news coverage?

Headlines about EYES stock have been trending negative this week, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Second Sight Medical Products earned a media sentiment score of -2.3 on InfoTrie's scale. They also assigned news articles about the medical device company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Second Sight Medical Products.

Who are some of Second Sight Medical Products' key competitors?

What other stocks do shareholders of Second Sight Medical Products own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Second Sight Medical Products investors own include Zynerba Pharmaceuticals (ZYNE), Adaptimmune Therapeutics (ADAP), Cara Therapeutics (CARA), Shopify (SHOP), Opko Health (OPK), Corbus Pharmaceuticals (CRBP), VBI Vaccines (VBIV), TransEnterix (TRXC), AVEO Pharmaceuticals (AVEO) and Plug Power (PLUG).

Who are Second Sight Medical Products' key executives?

Second Sight Medical Products' management team includes the folowing people:
  • Mr. Jonathan Will McGuire, CEO, Pres & Director (Age 56)
  • Mr. John T. Blake, CFO & Corp. Sec. (Age 43)
  • Mr. William Patrick Ryan, Chief Operating Officer (Age 58)
  • Gunnar Bjorg, Founder
  • Mr. Stephen D. Okland Jr., Chief Commercial Officer (Age 55)

When did Second Sight Medical Products IPO?

(EYES) raised $32 million in an IPO on Wednesday, November 19th 2014. The company issued 3,500,000 shares at a price of $9.00 per share. MDB Capital Group, LLC served as the underwriter for the IPO.

Who are Second Sight Medical Products' major shareholders?

Second Sight Medical Products' stock is owned by a number of of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (1.02%) and BlackRock Inc. (0.23%). Company insiders that own Second Sight Medical Products stock include Edward David Randolph, Gregg Williams, Jonathan Will Mcguire and Stephen D Okland. View Institutional Ownership Trends for Second Sight Medical Products.

Which institutional investors are selling Second Sight Medical Products stock?

EYES stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc. and BlackRock Inc.. Company insiders that have sold Second Sight Medical Products company stock in the last year include Edward David Randolph, Jonathan Will Mcguire and Stephen D Okland. View Insider Buying and Selling for Second Sight Medical Products.

How do I buy shares of Second Sight Medical Products?

Shares of EYES can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Second Sight Medical Products' stock price today?

One share of EYES stock can currently be purchased for approximately $0.81.

How big of a company is Second Sight Medical Products?

Second Sight Medical Products has a market capitalization of $100.60 million and generates $6.90 million in revenue each year. The medical device company earns $-35,090,000.00 in net income (profit) each year or ($0.52) on an earnings per share basis. Second Sight Medical Products employs 123 workers across the globe.View Additional Information About Second Sight Medical Products.

What is Second Sight Medical Products' official website?

The official website for Second Sight Medical Products is http://www.secondsight.com/.

How can I contact Second Sight Medical Products?

Second Sight Medical Products' mailing address is 12744 SAN FERNANDO ROAD SUITE 400, SYLMAR CA, 91342. The medical device company can be reached via phone at 818-833-5000 or via email at [email protected]


MarketBeat Community Rating for Second Sight Medical Products (NASDAQ EYES)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  207 (Vote Outperform)
Underperform Votes:  219 (Vote Underperform)
Total Votes:  426
MarketBeat's community ratings are surveys of what our community members think about Second Sight Medical Products and other stocks. Vote "Outperform" if you believe EYES will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EYES will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/18/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel